Impact of overactive bladder on quality of life and resource use: results from Korean Burden of Incontinence Study (KOBIS)

Table 1 Socio-demographics and disease characteristics of patients

	All patients	Incontinence episode per day
	All patients	0	1	2–3	≥4	p-value*
N	625	162	165	177	121	p-value*
Age (SD)	63.5 (12.0)	62.3 (12.2)	63.2 (13.3)	63.9 (11.6)	65.0 (10.3)	0.037
Female, %	422 (67.6)	93 (57.8)	100 (60.6)	131 (74.0)	98 (81.0)	<0.001
• % Post-menopausal	86.7	82.8	87.0	89.3	86.7	0.983
% retired	26.9	29.0	33.3	22.0	22.3	0.195
Education level, %
• Elementary/middle school	36.2	27.8	30.9	39.0	50.4	0.009
• High school graduate	36.4	36.4	38.2	39.0	30.6	0.690
• University graduate	27.4	35.8	30.9	22.0	19.0	0.020
Household income, %
• 0 – 50,000,000 KRW	74.8	69.3	77.8	78.4	79.1	0.341
• 50,000,001 – 100,000,000 KRW	16.3	19.7	14.8	11.9	20.5	0.793
• > 100,000,000 KRW	8.9	10.9	7.4	9.7	6.4	0.559
Health insurance coverage (%)
• National Health Insurance	71.5	71.6	69.7	70.1	76.0	0.909
• National Health Insurance and Private Insurance	26.3	27.2	27.9	27.6	20.7	0.515
• Public Assistance	2.2	1.2	2.4	2.3	3.3	0.110
OAB characteristics
Urinary incontinence, episodes/day (SD)	2.02 (2.31)	0 (0)	1 (0)	2.43 (0.50)	5.54 (2.80)	<0.001
Daytime urgency, episodes/day (SD)	3.95 (3.71)	2.78 (2.65)	3.19 (2.60)	3.90 (2.77)	6.64 (5.64)	<0.001
Daytime micturition, episodes/day (SD)	8.94 (4.29)	8.70 (6.27)	8.75 (3.24)	8.84 (3.16)	9.67 (3.63)	0.134
% with urinary frequency^a	43.4	36.4	41.2	44.6	53.7	0.002
Nocturia, episodes/day (SD)	2.39 (2.23)	1.95 (1.38)	2.44 (3.00)	2.33 (1.70)	3.00 (2.50)	0.006
Use of anti-cholinergic^b medication, n (%)
• Currently	41.6	50.0	45.5	39.0	28.9	<0.001
• In the past	8.3	4.3	6.1	9.0	15.7	0.001
• Never	50.1	45.7	48.5	52.0	55.4	0.019

*Comparison across severity groups conducted using linear or logistic regression for continuous and dichotomous outcomes, respectively. Where appropriate, analysis adjusted for age and gender
^aUrinary frequency defined as ≥9 micturition episodes per day
^bAnti-cholinergic medications include Tolterodine, Propiverine, Oxybuytnin, Trospium, Fesoterodine, Solifenacin, Flavoxate, and Imipramine

ISSN: 1477-7525